Antengene Corporation, a Chinese clinical stage therapeutics company focused on oncology, completed a $120m Series B financing.
The round, which follows a $21m Series A financing in 2017, was jointly led by Boyu Capital and FountainVest, with participation from Celgene Corporation, WuXi Corporate Venture Fund, and Taikang and previous investors Qiming Venture Partners and TF Capital.
The company intends to use the funds for the continuing development of its lead programs ATG-008 and ATG-010 (selinexor) and other clinical-stage assets, to expand its pipeline through internal R&D and external partnerships, and to prepare the commercial launch of late-stage drug candidates.
Founded in 2017 by Dr. Jay Mei, chairman and CEO, Antengene is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics.
The company’s pipeline includes five clinical stage products, ranging from Phase 2/3 to NDA stage, including ATG-010 for relapsed/refractory multiple myeloma, lymphomas and solid tumors, and ATG-008, which is in a multi-regional clinical trial that is currently enrolling late stage HCC patients in Taiwan, South Korea and mainland China.
Two other Phase 1 and Phase 2 clinical stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527, studied in a completed Phase 1 trial, is being explored for multiple anti-viral indications, including influenza, respiratory syncytial virus (RSV), and Epstein-Barr virus (EBV) related diseases.